• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Director Wood Timothy E converted options into 674 shares and covered exercise/tax liability with 169 shares, increasing direct ownership by 7% to 7,442 units (SEC Form 4)

    5/6/25 4:02:48 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $USNA alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    WOOD TIMOTHY E

    (Last) (First) (Middle)
    3838 WEST PARKWAY BLVD

    (Street)
    SALT LAKE CITY UT 84120

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    USANA HEALTH SCIENCES INC [ USNA ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    05/02/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 05/02/2025 M 674 A (1) 7,611 D
    Common Stock 05/02/2025 F 169 D $29.44 7,442 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Restricted Stock Units (1) 05/02/2025 M 674 (2) (2) Common Stock 674 $0 0 D
    Explanation of Responses:
    1. Each restricted stock unit represents a contingent right to receive one share of USNA common stock.
    2. Restricted Stock Units vest 25% on August 2, 2024, November 2, 2024, February 2, 2025, and May 2, 2025.
    Remarks:
    /s/ Joshua Foukas, Attorney-in-Fact 05/06/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $USNA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $USNA

    DatePrice TargetRatingAnalyst
    6/23/2023Buy
    Sidoti
    7/7/2022$78.00 → $53.00Hold → Underperform
    Jefferies
    4/14/2022$86.00Neutral
    DA Davidson
    More analyst ratings

    $USNA
    Financials

    Live finance-specific insights

    See more
    • USANA Health Sciences Reports First Quarter 2025 Results and Reiterates Full-Year Outlook

      USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal first quarter ended March 29, 2025. Key Financial Results First Quarter 2025 vs. First Quarter 2024 Net sales of $250 million versus $228 million, representing year-over-year growth of 10% and 12% in constant currency. Net earnings of $9.4 million versus $16.5 million. Diluted EPS of $0.49 as compared with $0.86. Adjusted diluted EPS(1) of $0.73 as compared with $0.86. Adjusted EBITDA(2) of $30 million versus $33 million. Direct selling Active Customers of 459,000 versus 494,000. Hiya Active Monthly Subscribers of 224,000. Company reiterates fiscal year 2025 outlook. Q1 2025 Financia

      4/22/25 4:05:00 PM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • USANA Schedules First Quarter 2025 Earnings Release and Conference Call

      USANA Health Sciences, Inc. (NYSE:USNA) today announced that first quarter 2025 results will be released after the close of market on Tuesday, April 22, 2025. Shortly following the issuance of the Company's earnings release, the Company will post its Management Commentary document on the Company's Investor Relations website (http://ir.usana.com) under the News/Events section. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the following morning, Wednesday, April 23, 2025 at 11:00 a.m. Eastern Time. The call will be broadcast over the Internet and can be accessed at http://ir.usana.com. About USANA USANA develops and manufactures hi

      4/8/25 4:05:00 PM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • USANA Health Sciences Reports Fourth Quarter and Full Year 2024 Results and Provides Fiscal Year 2025 Outlook

      USANA Health Sciences, Inc. (NYSE:USNA) (the "Company") today announced financial results for its fiscal fourth quarter and fiscal year ended December 28, 2024. The Company completed the acquisition of a 78.8% controlling ownership stake of Hiya Health Products, LLC ("Hiya") on December 23, 2024. Consequently, the Company's fourth quarter and fiscal year 2024 include the effect of less than a week of Hiya's operating results, which were not significant to the Company's consolidated results for the same periods. In light of the Hiya acquisition, the Company is now including metrics for Adjusted diluted EPS(1) and Adjusted EBITDA(2). Net earnings, Diluted EPS, Adjusted diluted EPS(1) and Adju

      2/25/25 4:10:00 PM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care

    $USNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF FINANCIAL OFFICER Iiekking G Doug sold $134,662 worth of shares (4,548 units at $29.61), closing all direct ownership in the company (SEC Form 4)

      4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

      5/12/25 10:42:33 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Wood Timothy E converted options into 674 shares and covered exercise/tax liability with 169 shares, increasing direct ownership by 7% to 7,442 units (SEC Form 4)

      4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

      5/6/25 4:02:48 PM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Winssinger Frederic J converted options into 674 shares, increasing direct ownership by 13% to 5,871 units (SEC Form 4)

      4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

      5/6/25 4:01:06 PM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care

    $USNA
    Leadership Updates

    Live Leadership Updates

    See more
    • USANA Exec. Chairman Kevin Guest Celebrates Guitar Month, Stress Awareness Month for Harmony

      SALT LAKE CITY, April 1, 2025 /PRNewswire/ -- USANA Health Sciences (NYSE:USNA) Executive Chairman Kevin Guest marks April's convergence of International Guitar Month and Stress Awareness Month, as a perfect pairing that celebrates the healing power of music for mental well-being. While music has long been heralded as a universal remedy, the guitar offers far more than just melodies. Studies, stories and specialists alike agree: playing the guitar is a proven method to reduce stress. A passionate, performing guitarist himself, Guest invites others to join the cause. "Music has

      4/1/25 7:47:00 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • USANA Appoints New Chief Scientific Officer

      Dr. Kathryn Armstrong brings 17 years of scientific expertise to the company SALT LAKE CITY, Jan. 22, 2025 /PRNewswire/ -- USANA Health Sciences, Inc., a global leader in cellular nutrition, is proud to announce that Dr. Kathryn Armstrong, Ph.D., will be assuming the role of chief scientific officer at the company. Kathryn has served as USANA's executive vice president of research and development since July of 2024.  Kathryn's predecessor, Dr. Rob Sinnott, announced his retirement at the end of 2024, but will continue to assist in the company's pursuit for scientific excellence as its senior scientific fellow.

      1/22/25 7:07:00 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • USANA Executive Chairman Kevin Guest Encourages Connections with July's "Social Wellness Month"

      SALT LAKE CITY, July 1, 2024 /PRNewswire/ -- Throughout July, Kevin Guest, executive chairman at USANA Health Sciences (NYSE:USNA), is emphasizing boosting social connections during "Social Wellness Month." Social wellness—the ability to form meaningful relationships and interact positively with others—not only enhances our emotional well-being but also significantly impacts our overall health. "Strong social connections reduce stress, improve mental health, and even extend life expectancy," said Guest. "In a world where digital interactions often replace face-to-face communic

      7/1/24 7:13:00 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care

    $USNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Sidoti initiated coverage on USANA

      Sidoti initiated coverage of USANA with a rating of Buy

      6/23/23 9:12:38 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • USANA downgraded by Jefferies with a new price target

      Jefferies downgraded USANA from Hold to Underperform and set a new price target of $53.00 from $78.00 previously

      7/7/22 9:35:48 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • DA Davidson initiated coverage on USANA with a new price target

      DA Davidson initiated coverage of USANA with a rating of Neutral and set a new price target of $86.00

      4/14/22 7:45:27 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care

    $USNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $USNA
    SEC Filings

    See more

    $USNA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SEC Form SC 13G/A filed by USANA Health Sciences Inc. (Amendment)

      SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

      2/13/24 10:49:58 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by USANA Health Sciences Inc. (Amendment)

      SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

      2/13/23 11:26:45 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by USANA Health Sciences Inc. (Amendment)

      SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

      2/11/22 3:48:24 PM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 10-Q filed by USANA Health Sciences Inc.

      10-Q - USANA HEALTH SCIENCES INC (0000896264) (Filer)

      5/6/25 2:42:26 PM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form DEFA14A filed by USANA Health Sciences Inc.

      DEFA14A - USANA HEALTH SCIENCES INC (0000896264) (Filer)

      5/1/25 4:44:16 PM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by USANA Health Sciences Inc.

      SCHEDULE 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

      4/30/25 11:13:38 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • USANA Releases 2024 Sustainability Report

      Highlighting USANA's ongoing commitment to people, planet, and products SALT LAKE CITY, May 8, 2025 /PRNewswire/ -- As a global leader in health and wellness, USANA is dedicated to doing its part in creating a better, healthier world. And with a commitment to positive business practices, USANA recently released its fifth annual sustainability report. This review of USANA's 2024 sustainability efforts and progress includes organizational priorities based on a comprehensive stakeholder assessment. To view the full 2024 sustainability report, please click here. "In unveiling our

      5/8/25 8:56:00 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • Kevin Guest Shares Transformative Success Strategies on Executive Coaching Day, May 1

      SALT LAKE CITY, May 1, 2025 /PRNewswire/ -- Kevin Guest, Executive Chairman at USANA Health Sciences (NYSE:USNA) and acclaimed author of All the Right Reasons, 12 Timeless Principles for Living a Life in Harmony, is sharing valuable insights for professionals striving to reach their peak potential. As part of Executive Coaching Day on May 1, Guest is combining decades of leadership experience with principles outlined in his bestselling book to offer actionable steps for success both in the boardroom and in life. "True success isn't just about achieving your goals; it's about l

      5/1/25 7:47:00 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • USANA Celavive Postbiotic Rescue Serum Selected as a Good Housekeeping 2025 Beauty Award Winner

      SALT LAKE CITY, April 28, 2025 /PRNewswire/ -- USANA Health Sciences, Inc., a global leader in cellular nutrition, announced today that its Celavive Postbiotic Rescue Serum was named as a winner in Good Housekeeping's 2025 Beauty Awards. The full list of awards can be found here. To learn more about USANA and the science behind its products, please visit USANA.com. "We're so excited that our Postbiotic Rescue Serum has been named a Good Housekeeping 2025 Beauty Award winner," said Brent Neidig, USANA's chief commercial officer. "Our product and R&D teams have put so much time

      4/28/25 7:27:00 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care